The FDA Approves Use of Sculptra (New-Fill) for Treatment of Lipoatrophy or Facial Fat Loss
August 30, 2004
On August 4, 2004, the U.S. Food and Drug Administration, or FDA, approved Dermik laboratories's Sculptra, also known as New-Fill, for the treatment of facial fat loss (lipoatrophy) in individuals living with HIV/AIDS. Sunken cheeks are one of the most noticeable effects of lipoatrophy. A large percentage of people living with HIV/AIDS experience some kind of fat loss in the face or arms and legs.
The loss of facial fat has further stigmatized people living with the disease and the approval of Sculptra may help to correct that problem in some. Treatments with Sculptra aren't cheap and they do not have a permanent effect. There is anecdotal evidence of patients needing injections every 12 to 15 months. The injectable poly-L-lactic acid is a polymer synthetically derived from natural components that is injected under the skin to improve facial contours. There are some visible delayed side effects like bumps under the skin and redness. Bruising and swelling are also common on the area being treated.
For more information, go to the product's Web site: www.Sculptra.com/US.
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.